phase iv Health Economics and Outcomes Research

Generating relevant economic and humanistic evidence for a variety of different stakeholders, health authorities and technology assessment agencies requires a multidisciplinary approach to the design, execution, and analysis of data. Using internal resources and external global partners, PharmaNet/i3's Phase IV HEOR team addresses such complicating factors as the differing approach to healthcare delivery and the cost of healthcare resources in different countries. PharmaNet/i3's HEOR studies and analyses focus on the economic impact of treatments, diseases, and conditions, including the direct costs of medical expenditures and indirect costs, such as those associated with work loss and disability.

PharmaNet/i3's experienced HEOR team supports clients establishing product value through a broad range of services, including:

• Portfolio planning
• Comprehensive economic and outcomes literature reviews
• Burden/cost of illness studies
• Treatment pattern analyses
• Trial/market simulation modeling
• Global cost-effectiveness models
• Management of economic endpoints in clinical trials
• Patient Reported Outcome (PRO) studies, including Quality-of-Life and health utility studies
• Retrospective cost-effectiveness and resource utilization studies
• Global and country-specific value dossiers
• Pricing and market access research